A Randomized, Eight-Week Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy.
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Aliskiren/amlodipine (Primary) ; Aliskiren
- Indications Essential hypertension
- Focus Biomarker; Therapeutic Use
- Sponsors Novartis
- 24 Jan 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 30 Jun 2011 Additional locations identified as reported by ClinicalTrials.gov record.
- 25 Dec 2010 Additional lead trial investigator identified as reported by Clinical Trials Registry - India record.